Skip to main content
Erschienen in: Intensive Care Medicine 9/2003

01.09.2003 | Original

The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis

verfasst von: Christian Brun-Buisson, Françoise Roudot-Thoraval, Emmanuelle Girou, Catherine Grenier-Sennelier, Isabelle Durand-Zaleski

Erschienen in: Intensive Care Medicine | Ausgabe 9/2003

Einloggen, um Zugang zu erhalten

Abstract

Objective

To document the costs and outcomes of the various forms of the septic syndromes [systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock), particularly those associated with infection acquired in an intensive care unit (ICU).

Design

Prospective data collection for all septic patients admitted to a medical ICU during a 1-year period. Costs were computed from the viewpoint of the hospital.

Results

Mean total hospital costs were €26,256, €35,185, and €27,083 for patients with sepsis, severe sepsis, and septic shock, respectively. Total costs varied slightly according to the site of infection and the severity of sepsis but were influenced mostly by its mode of acquisition: patients having sepsis associated with ICU-acquired infection incurred total costs about three times those of patients presenting with infection and sepsis on ICU admission (from €39,908 in patients with ICU acquired sepsis to €44,851 in patients with ICU-acquired septic shock). Stratifying patients by the presence of ICU-acquired infection also showed that a first episode of infection complicated by ICU-acquired sepsis incurred at least 2.5 times more costs than a single episode of sepsis.

Conclusions

In this series the medical costs of sepsis were not markedly influenced by its severity but by its mode of acquisition. Due to wide variations in ICU costs cost-effectiveness analyses of treatments for sepsis should document the case-mix of patients and the contribution to this of nosocomial infections.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bone RC, Balk RA, Cerra FB, Dellinger EP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, the ACCP/SCCM Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1656–1662PubMed Bone RC, Balk RA, Cerra FB, Dellinger EP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, the ACCP/SCCM Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1656–1662PubMed
2.
Zurück zum Zitat Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274:968–974PubMed Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274:968–974PubMed
3.
Zurück zum Zitat Brun-Buisson C, Doyon F, Carlet J (1996) Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 154:617–624PubMed Brun-Buisson C, Doyon F, Carlet J (1996) Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 154:617–624PubMed
4.
Zurück zum Zitat Pittet D, Thiévent B, Wenzel RP, Li N, Auckenthaler R, Suter PM, Thievent B (1996) Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 153:684–693PubMed Pittet D, Thiévent B, Wenzel RP, Li N, Auckenthaler R, Suter PM, Thievent B (1996) Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 153:684–693PubMed
5.
Zurück zum Zitat Rangel-Frausto MS, Pittet D, Costigan MD, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome. JAMA 273:117–123PubMed Rangel-Frausto MS, Pittet D, Costigan MD, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome. JAMA 273:117–123PubMed
6.
Zurück zum Zitat Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL, Platt R (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 277:234–240 Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL, Platt R (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 277:234–240
7.
Zurück zum Zitat Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21:302–309PubMed Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21:302–309PubMed
8.
Zurück zum Zitat Barriere SL (1992) The economic impact of HA-1A (Centoxin) against endotoxin. Pharmacoeconomics 2:408–413PubMed Barriere SL (1992) The economic impact of HA-1A (Centoxin) against endotoxin. Pharmacoeconomics 2:408–413PubMed
9.
Zurück zum Zitat Chalfin DB, Holbein MEB, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269:249–254CrossRefPubMed Chalfin DB, Holbein MEB, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269:249–254CrossRefPubMed
10.
Zurück zum Zitat Schulman KA, Glick HA, Rubin H, Eisenberg JM (1991) Cost-effectiveness of HA-1A monoclonal antibodies for gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA 266:3466–3471CrossRefPubMed Schulman KA, Glick HA, Rubin H, Eisenberg JM (1991) Cost-effectiveness of HA-1A monoclonal antibodies for gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA 266:3466–3471CrossRefPubMed
11.
Zurück zum Zitat Hout BA van, Birnie E, Redekop WK, Lorijn RH, Bossuyt PM, Rutten FF (1994) Cost-effectiveness of HA-1A treatment for patients with sepsis. Prog Clin Biol Res 388:435–43PubMed Hout BA van, Birnie E, Redekop WK, Lorijn RH, Bossuyt PM, Rutten FF (1994) Cost-effectiveness of HA-1A treatment for patients with sepsis. Prog Clin Biol Res 388:435–43PubMed
12.
Zurück zum Zitat Teres D, Rapoport J, Lemeshow S, Kim S, Akhras K (2002) Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med 30:2413–2419PubMed Teres D, Rapoport J, Lemeshow S, Kim S, Akhras K (2002) Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med 30:2413–2419PubMed
13.
Zurück zum Zitat Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMed Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMed
14.
Zurück zum Zitat Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, Le Gall JR, The European Sepsis Group (2002) Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med 28:108–121 (erratum p 526)PubMed Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, Le Gall JR, The European Sepsis Group (2002) Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med 28:108–121 (erratum p 526)PubMed
15.
Zurück zum Zitat Kreger BE, Craven DE, Carling P, McCabe WR (1980) Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 68:332–343PubMed Kreger BE, Craven DE, Carling P, McCabe WR (1980) Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 68:332–343PubMed
16.
Zurück zum Zitat Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) A model to compute the medical cost of intensive care patients. Pharmacoeconomics 15:573–582PubMed Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) A model to compute the medical cost of intensive care patients. Pharmacoeconomics 15:573–582PubMed
17.
Zurück zum Zitat Sznajder M, Leleu G, Buonamico G, Auvert B, Aegerter P, Merlière Y, Dutheil M, Guidet B, Le Gall JR (1998) Estimation of direct cost and resource allocation in intensive care: correlation with Omega system. Intensive Care Med 24:582–589 Sznajder M, Leleu G, Buonamico G, Auvert B, Aegerter P, Merlière Y, Dutheil M, Guidet B, Le Gall JR (1998) Estimation of direct cost and resource allocation in intensive care: correlation with Omega system. Intensive Care Med 24:582–589
18.
Zurück zum Zitat Tierney WM, Fitzgerald JF, Miller ME, James MK, McDonald CJ (1995) Predicting inpatient costs with admitting clinical data. Med Care 33:1–14PubMed Tierney WM, Fitzgerald JF, Miller ME, James MK, McDonald CJ (1995) Predicting inpatient costs with admitting clinical data. Med Care 33:1–14PubMed
19.
Zurück zum Zitat Barnett PG (1997) Research without billing data. Econometric estimation of patient-specific costs. Med Care 35:553–563CrossRefPubMed Barnett PG (1997) Research without billing data. Econometric estimation of patient-specific costs. Med Care 35:553–563CrossRefPubMed
20.
Zurück zum Zitat Slatyer MA, James OF, Moore PG, Leeder SR (1986) Costs, severity of illness and outcome in intensive care. Anaesth Intensive Care 14:381–389PubMed Slatyer MA, James OF, Moore PG, Leeder SR (1986) Costs, severity of illness and outcome in intensive care. Anaesth Intensive Care 14:381–389PubMed
21.
Zurück zum Zitat Thompson SG, Barber JA (2002) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197–1200 Thompson SG, Barber JA (2002) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197–1200
22.
Zurück zum Zitat Pittet D, Tarara D, Wenzel RP (1994) Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 271:1598–1601PubMed Pittet D, Tarara D, Wenzel RP (1994) Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 271:1598–1601PubMed
23.
Zurück zum Zitat Linden PK, Angus DC, Chelluri L, Branch RA (1995) The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. J Crit Care 10:154–164PubMed Linden PK, Angus DC, Chelluri L, Branch RA (1995) The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. J Crit Care 10:154–164PubMed
24.
Zurück zum Zitat Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310PubMed Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310PubMed
25.
Zurück zum Zitat Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347:993–1000CrossRefPubMed Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347:993–1000CrossRefPubMed
26.
Zurück zum Zitat Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 282:1745–1751PubMed Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C (1999) Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 282:1745–1751PubMed
Metadaten
Titel
The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis
verfasst von
Christian Brun-Buisson
Françoise Roudot-Thoraval
Emmanuelle Girou
Catherine Grenier-Sennelier
Isabelle Durand-Zaleski
Publikationsdatum
01.09.2003
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 9/2003
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-003-1877-x

Weitere Artikel der Ausgabe 9/2003

Intensive Care Medicine 9/2003 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.